FIELD: pharmaceutics.
SUBSTANCE: invention relates to pharmaceutical industry and concerns composition for preventing or treating diabetes, as well as method of treating diabetes. Long-acting insulin conjugate and long-acting insulinotropic peptide conjugate are obtained by binding insulin or insulinotropic peptide with region of immunoglobulin Fc via non-peptide linker to improve duration of effect and stability in vivo. Accompanying administration of long-acting conjugate of insulin and long-acting insulinotropic peptide conjugate inhibits increase of body weight, caused by insulin treatment, vomiting and nausea, caused by insulinotropic peptide treatment, and reduces required dose of insulin.
EFFECT: invention consists in fact that composition contains long-acting insulin conjugate and long-acting insulinotropic peptide conjugate.
20 cl, 3 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LIQUID COMPOSITION OF LONG-ACTING INSULIN AND INSULINOTROPIC PEPTIDE | 2013 |
|
RU2643766C2 |
| PHARMACEUTICAL COMPOSITION FOR NON-ALCOHOLIC FATTY LIVER DISEASE PREVENTION OR TREATMENT | 2013 |
|
RU2635966C2 |
| LIQUID FORMULATION OF LONG-ACTING INSULIN CONJUGATE | 2013 |
|
RU2670270C2 |
| CONJUGATE, CONTAINING OXYNTOMODULIN AND FRAGMENT OF IMMUNOGLOBULIN, AND USE THEREOF | 2012 |
|
RU2607365C2 |
| LIQUID FORMULATION OF LONG-ACTING INSULINOTROPIC PEPTIDE CONJUGATE | 2013 |
|
RU2671576C2 |
| CONJUGATE CONTAINING OXINTOMODULIN AND IMMUNOGLOBULIN FRAGMENT, AND ITS APPLICATION | 2012 |
|
RU2733544C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY-RELATED DISEASES CONTAINING INSULINOTROPIC PEPTIDE CONJUGATE | 2008 |
|
RU2446816C2 |
| CONJUGATE OF LONG-ACTING PHYSIOLOGICALLY ACTIVE SUBSTANCE AND ITS USE | 2018 |
|
RU2773823C2 |
| SITE-SPECIFIC INSULIN CONJUGATE | 2014 |
|
RU2677800C2 |
| INSULINOTROPIC COMPLEX IN WHICH IMMUNOGLOBULIN FRAGMENT IS USED | 2008 |
|
RU2436589C2 |
